Loading
NASDAQConsumer DefensiveHousehold & Personal Products
Latest quote
$22.47
+$2.07 · +10.15%
Prenetics Global Limited is a consumer health sciences company that has pivoted to focus on a consumer health and longevity platform. The company's main brand is IM8, which offers science-backed nutritional supplements. It also operates CircleDNA, a consumer genetic testing brand that provides personalized health reports based on sequencing technology.
Previous close
$22.47
+$2.07 · +10.15%
After-hours
$22.47
$0.00 · 0.00%
Oct 7, 7:30 PM ET
Regular session · ET · Market data may be delayed.
Prenetics Global Limited is a consumer health sciences company that has pivoted to focus on a consumer health and longevity platform. The company's main brand is IM8, which offers science-backed nutritional supplements. It also operates CircleDNA, a consumer genetic testing brand that provides personalized health reports based on sequencing technology.
Day range
Current $22.47
52-week range
Current $22.47
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
74
Undervalued
Sentiment
43
Mixed
Risk
50
Elevated Risk
Momentum
47
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Prenetics Global Limited is a consumer health sciences company that has pivoted to focus on a consumer health and longevity platform. The company's main brand is IM8, which offers science-backed nutritional supplements. It also operates CircleDNA, a consumer genetic testing brand that provides personalized health reports based on sequencing technology.
Day range
Current $22.47
52-week range
Current $22.47
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 92.39M USD | 30.62M USD | 21.74M USD | 13.16M USD | 12.53M USD |
| Cost of goods sold | 43.6M USD | 15.22M USD | 12.91M USD | 9.55M USD | 8.93M USD |
| Gross profit | 48.79M USD | 15.4M USD | 8.83M USD | 3.62M USD | 3.6M USD |
| Research and development | 5.13M USD | 10.92M USD | 11.66M USD | 5.99M USD | 6.39M USD |
| Selling, general, and administrative | 79.8M USD | 55.37M USD | 49.68M USD | 64.08M USD | 53.67M USD |
| Operating expenses | 86.92M USD | 63.54M USD | 60.74M USD | 69.64M USD | 60.26M USD |
| Interest income | 1.04M USD | 2.04M USD | 3.92M USD | 472K USD | 201 USD |
| Interest expense | 241K USD | 203K USD | 119.66K USD | 242K USD | 42.23K USD |
| Depreciation and amortization | 3.78M USD | 5.93M USD | 7.79M USD | 7.54M USD | 7.35M USD |
| Operating income | −38.13M USD | −48.14M USD | −51.91M USD | −66.02M USD | −56.66M USD |
| Net income | −37.71M USD | −46.3M USD | −62.72M USD | −190.45M USD | −174.01M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$37.50
66.89% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Nov 14, 2023 | 1:15 | — | — |
Stock split | May 18, 2022 | 129:100 | — | — |
Effective Nov 14, 2023
1:15
Effective May 18, 2022
129:100
Funds reporting this stock among their holdings, ordered by reported position size.
State Street SPDR Portfolio Emerging Markets ETFSPEM
State Street SPDR S&P Emerging Markets Small Cap ETFEWX
State Street SPDR S&P International Small Cap ETFGWXAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
